LambdaVision

Executive Summary

LambdaVision is pioneering the first protein-based artificial retina to restore meaningful vision for patients blinded by advanced retinal degenerative diseases such as retinitis pigmentosa (RP) and age-related macular degeneration (AMD). The company's platform uses light-sensitive proteins similar to rhodopsin, naturally found in the eye, to create a biocompatible artificial retina that replaces lost photoreceptor cells. This innovative approach aims to address a significant unmet need, as current treatments for RP and AMD are limited to slowing disease progression or providing partial vision restoration. LambdaVision's technology has the potential to offer a durable, scalable solution for millions of patients worldwide. The company has made progress in preclinical studies demonstrating the safety and efficacy of its protein-based retina in animal models, and it is advancing toward clinical development. While still in the early stages, LambdaVision's platform is supported by academic collaborations and a strong intellectual property portfolio. The company is actively seeking funding and partnerships to support IND-enabling studies and initial clinical trials. If successful, LambdaVision could become a leader in the emerging field of protein-based retinal prosthetics, offering a novel therapeutic option for patients with profound vision loss.

Upcoming Catalysts (preview)

• Q4 2026FDA IND Clearance for Phase 1/2 Trial60% success
• H2 2026Series B Financing Round70% success
• TBDStrategic Partnership with Ophthalmic Company40% success